FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document | 
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-14 | SC 13G | SC 13G | View Document | 
| 2022-02-14 | 6-K | TRANSFER OF TREASURY SHARES | View Document | 
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document | 
| 2022-02-10 | SC 13G | SCHEDULE 13G | View Document | 
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document | 
| 2022-02-10 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document | 
| 2022-02-10 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document | 
| 2022-02-10 | 6-K | BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS | View Document | 
| 2022-02-09 | 6-K | FINAL RESULTS | View Document | 
| 2022-02-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-02-07 | SC 13G/A | View Document | |
| 2022-02-07 | 6-K | PUBLICATION OF FULL YEAR 2021 RESULTS | View Document | 
| 2022-02-02 | 6-K | GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD | View Document | 
| 2022-02-01 | 6-K | FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA | View Document | 
| 2022-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2022-01-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-19 | 6-K | TONY WOOD APPOINTED CSO DESIGNATE, GSK | View Document | 
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-18 | 6-K | UPDATE - GSK CONSUMER HEALTHCARE | View Document | 
| 2022-01-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2022-01-11 | 6-K | US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES | View Document | 
| 2022-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-12-21 | 6-K | VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE | View Document | 
| 2021-12-20 | 6-K | CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED | View Document | 
| 2021-12-17 | 6-K | XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 | View Document | 
| 2021-12-15 | 6-K | GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE | View Document | 
| 2021-12-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-12-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-12-07 | 6-K | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA | View Document | 
| 2021-12-07 | 6-K | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document | 
| 2021-12-02 | 6-K | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document | 
| 2021-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-11-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-11-24 | 6-K | GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES | View Document | 
| 2021-11-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-11-17 | 6-K | NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS | View Document | 
| 2021-11-15 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document | 
| 2021-11-12 | 6-K | PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB | View Document | 
| 2021-11-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-11-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-11-05 | 6-K | GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT | View Document | 
| 2021-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-10-27 | 6-K | 3RD QUARTER RESULTS | View Document | 
| 2021-10-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-27 | 6-K | DIRECTORATE CHANGE | View Document | 
| 2021-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-09-27 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document | 
| 2021-09-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-20 | 6-K | DIRECTOR DECLARATION | View Document | 
| 2021-09-16 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document | 
| 2021-09-16 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document | 
| 2021-09-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-08 | UPLOAD | View Document | |
| 2021-09-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-03 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-08-31 | CORRESP | View Document | |
| 2021-08-31 | 6-K | SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL | View Document | 
| 2021-08-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-08-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-08-18 | UPLOAD | View Document | |
| 2021-08-13 | 6-K/A | DIRECTOR/PDMR SHAREHOLDING - AMENDMENT | View Document | 
| 2021-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-08-05 | 6-K | BLOCK LISTING APPLICATION | View Document | 
| 2021-08-02 | 6-K | TOTAL VOTING RIGHTS | View Document | 
| 2021-07-28 | 6-K | 2ND QUARTER RESULTS | View Document | 
| 2021-07-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-07-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
| 2021-07-23 | 6-K | BOARD COMMITTEE CHANGES | View Document | 
| 2021-07-22 | 6-K | CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY | View Document | 
| 2021-07-16 | 6-K | GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS | View Document | 
| 2021-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document | 
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.